PMID- 33818480
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20240402
IS  - 0971-5916 (Print)
IS  - 0975-9174 (Electronic)
IS  - 0971-5916 (Linking)
VI  - 153
IP  - 1 & 2
DP  - 2021 Jan & Feb
TI  - Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
PG  - 219-226
LID - 10.4103/ijmr.IJMR_2294_20 [doi]
AB  - BACKGROUND & OBJECTIVES: Hydroxychloroquine (HCQ), reported to inhibit severe 
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in in vitro 
      studies, has been recommended for prophylaxis of COVID-19 in healthcare workers 
      (HCWs). The objective of this study was to assess short-term adverse events (AEs) 
      of HCQ in HCWs. METHODS: This cross-sectional study among consenting HCWs taking 
      prophylaxis and working in hospitals with COVID-19 patients used online forms to 
      collect details of HCWs, comorbidities, prophylactic drugs used and AEs after the 
      first dose of HCQ. Verification of dose and AEs was done by personal contact. 
      Multivariate logistic regression analysis was done to determine the effect of 
      age, gender and dose of HCQ on AE. RESULTS: Of the 1303 HCWs included, 98.4 per 
      cent (n=1282) took HCQ and 66 per cent (n=861) took 800 mg as first day's dose. 
      Among the 19.9 per cent (n=259) reporting AEs, 1.5 per cent (n=20) took treatment 
      for AE, none were hospitalized and three discontinued HCQ. Gastrointestinal AEs 
      were the most common (172, 13.2%), with less in older [odds ratio (OR) 0.56, 95% 
      confidence interval (CI) 0.35-0.89], with more in females (OR 2.46, 95% CI 
      1.78-3.38) and in those taking a total dose of 800 mg on day one compared to a 
      lower dose. Hypoglycaemia (1.1%, n=14), cardiovascular events (0.7%, n=9) and 
      other AEs were minimal. INTERPRETATION & CONCLUSIONS: HCQ prophylaxis first dose 
      was well tolerated among HCWs as evidenced by a low discontinuation. For adverse 
      effects, a small number required treatment, and none required hospitalization. 
      The study had limitations of convenience sampling and lack of laboratory and 
      electrocardiography confirmation of AEs.
FAU - Faruqui, Atiya R
AU  - Faruqui AR
AD  - Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, 
      India.
FAU - Xavier, Denis
AU  - Xavier D
AD  - Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, 
      India.
FAU - Kamat, Sandhya K
AU  - Kamat SK
AD  - Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical 
      College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
FAU - Chandy, Sujith J
AU  - Chandy SJ
AD  - Department of Pharmacology & Clinical Pharmacology, Christian Medical College, 
      Vellore, Tamil Nadu, India.
FAU - Medhi, Bikash
AU  - Medhi B
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education & 
      Research, Chandigarh, India.
FAU - Tripathi, Raakhi K
AU  - Tripathi RK
AD  - Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical 
      College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
FAU - Shetty, Yashashri C
AU  - Shetty YC
AD  - Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical 
      College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
FAU - Raj, John Michael
AU  - Raj JM
AD  - Department of Biostatistics, St. John's Medical College, Bengaluru, Karnataka, 
      India.
FAU - Kaushal, Sandeep
AU  - Kaushal S
AD  - Department of Pharmacology, Dayanand Medical College & Hospital, Ludhiana, 
      Punjab, India.
FAU - Balakrishnan, S
AU  - Balakrishnan S
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, 
      Madhya Pradesh, India.
FAU - Atal, Shubham
AU  - Atal S
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, 
      Madhya Pradesh, India.
FAU - Tripathi, Santanu K
AU  - Tripathi SK
AD  - Department of Clinical & Experimental Pharmacology, School of Tropical Medicine, 
      Kolkata, West Bengal, India.
FAU - Badyal, Dinesh K
AU  - Badyal DK
AD  - Department of Pharmacology, Christian Medical College, Ludhiana, Punjab, India.
FAU - Dikshit, Harihar
AU  - Dikshit H
AD  - Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, 
      Bihar, India.
FAU - Roy, Sukalyan Saha
AU  - Roy SS
AD  - Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, 
      Bihar, India.
FAU - Trivedi, Niyati
AU  - Trivedi N
AD  - Department of Pharmacology, Medical College Baroda, Vadodara, Ahmedabad, Gujarat, 
      India.
FAU - Chatterjee, Suparna
AU  - Chatterjee S
AD  - Department of Pharmacology, Institute of Postgraduate Medical Education & 
      Research, Kolkata, West Bengal, India.
FAU - Desai, Chetna
AU  - Desai C
AD  - Department of Pharmacology, B.J. Medical College, Ahmedabad, Gujarat, India.
FAU - Tripathi, C D
AU  - Tripathi CD
AD  - Department of Pharmacology, Vardhman Mahavir Medical College & Safdarjung 
      Hospital, New Delhi, India.
FAU - Rege, Nirmala N
AU  - Rege NN
AD  - Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical 
      College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
FAU - Gupta, Pooja
AU  - Gupta P
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Raveendran, R
AU  - Raveendran R
AD  - Department of Pharmacology, Jawaharlal Institute of Postgraduate Education & 
      Research, Puducherry, India.
FAU - Kaul, Rajni
AU  - Kaul R
AD  - Division of Basic Medical Sciences, New Delhi, India.
FAU - Kshirsagar, Nilima A
AU  - Kshirsagar NA
AD  - National Chair Clinical Pharmacology, Indian Council for Medical Research, New 
      Delhi, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - COVID-19/*prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Personnel
MH  - Humans
MH  - *Hydroxychloroquine/adverse effects/therapeutic use
MH  - Male
MH  - Pre-Exposure Prophylaxis
MH  - *COVID-19 Drug Treatment
PMC - PMC8184065
OTO - NOTNLM
OT  - Adverse events
OT  - COVID-19
OT  - chloroquine
OT  - coronavirus
OT  - healthcare workers
OT  - hydroxychloroquine
OT  - prophylaxis
OT  - rational
COIS- None
EDAT- 2021/04/06 06:00
MHDA- 2021/04/16 06:00
PMCR- 2021/01/01
CRDT- 2021/04/05 12:36
PHST- 2021/04/05 12:36 [entrez]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - IndianJMedRes_2021_153_1_219_311938 [pii]
AID - IJMR-153-219 [pii]
AID - 10.4103/ijmr.IJMR_2294_20 [doi]
PST - ppublish
SO  - Indian J Med Res. 2021 Jan & Feb;153(1 & 2):219-226. doi: 
      10.4103/ijmr.IJMR_2294_20.